top of page


Celltrion licenses Kaigene anti-APRIL antibody KG013 for up to $580.5 million
Celltrion has licensed Kaigene's next-generation anti-APRIL antibody KG013 in a global agreement worth up to $580.5 million plus royalties.

nuaxia
Oct 232 min read


FDA grants accelerated approval to AstraZeneca Ultomiris for primary IgA nephropathy in adults
The FDA has granted accelerated approval to AstraZeneca's Ultomiris for adults with primary IgA nephropathy, introducing a C5 complement inhibitor treatment to reduce proteinuria.

nuaxia
Oct 222 min read


FDA Approves Trutakna as First Dual BAFF/APRIL Targeted Therapy for IgA Nephropathy
Vera Therapeutics’ Trutakna becomes the first FDA-approved therapy targeting both BAFF and APRIL pathways, introducing a new immune-based approach for adults with progressive IgA nephropathy.

nuaxia
Jul 82 min read
bottom of page